



# Balloon-expandable TAVI valves have proven durability at 5 years with a promising outlook for the future



At 5 years, transcatheter valve implantation (TAVI) and surgical aortic valve replacement (sAVR) durability are equivalent<sup>1</sup>




Mean aortic valve area: p=0.29; Mean valve gradient: p=0.92


There are no significant differences in<sup>1</sup>:




Very few patients who received TAVI required reintervention due to structural valve deterioration (SVD)<sup>2</sup>



# TAVI valves are tested with even more rigorous criteria for measuring SVD and bioprosthetic valve failure (BVF)



## Even so, studies still show very low rates of SVD and BVF at 8 years after TAVI<sup>4</sup>



At 2-year follow-up on the PARTNER 3 Trial, there was no change in mean gradient, aortic valve area or paravalvular regurgitation. Patients will be followed up to ten years.<sup>5</sup>



**References:** 1. Mack et al. Lancet 2015;385:2477-84. 2. Douglas et al. JAMA Cardiol 2017; 2(11): 1197-1206. 3. Dvir D, Bourguignon T, Otto CM, et al. Circulation. 2018;137(4):388-399. 4. Eltchaninoff H, et al. Eurointervention 2018; 14(3): e264-e271. 5. Mack MJ. Two-year clinical and echocardiographic outcomes from the PARTNER 3 low-risk randomized trial. Presented at: ACC 2020, Chicago, March 29, 2020.

Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, and PARTNER 3 are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP--EU-0141 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com